Glaxosmithkline Pharmaceuticals Ltd vs Solara Active Pharma Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2484 as of 08 May 16:01 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Solara Active Pharma Sciences Ltd changed from 22.6 on March 2021 to 3943 on March 2025 . This represents a CAGR of 180.78% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Solara Active Pharma Sciences Ltd changed from ₹ 5009 crore on March 2021 to ₹ 2005 crore on March 2025 . This represents a CAGR of -16.73% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 349 crore as compare to the Sep '25 revenue of ₹ 314.03 crore. This represent the growth of 11.14% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 30.59 crore as compare to the Sep '25 ebitda of ₹ 35.22 crore. This represent the decline of -13.15% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Solara Active Pharma Sciences Ltd changed from ₹ -13.46 crore to ₹ -17.43 crore over 7 quarters. This represents a CAGR of 15.92% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Solara Active Pharma Sciences Ltd changed from 11.38 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs).
The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru. The Company offer rich basket of niche high-value products for global markets.
The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others.
These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Solara Active Pharma Sciences Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,994 Cr while Market cap of Solara Active Pharma Sciences Ltd is 1,865 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd?

As of May 8, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2478.95. On the other hand, Solara Active Pharma Sciences Ltd stock price is INR ₹515.85.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Solara Active Pharma Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.